14 July 2022
Accrufer® New Drug Submission accepted by Health Canada
Shield Therapeutics plc announces that Health Canada have screened and accepted the Accrufer® New Drug Submission (“NDS”), filed by Shield’s Licensing Partner, KYE Pharmaceuticals Inc. (“KYE”) earlier this year.
For full details click here.